Sep 12, 2023 / 12:10PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
All right. Good morning, everyone, to day 2 of the Morgan Stanley Healthcare Conference. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at MS.
It's my pleasure to host Avantor this morning. And on behalf of the company, we have Michael Stubblefield, CEO. Thank you for joining us, Michael.
Before we get started, just some important disclosures, please use the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo Michael, maybe just to kick things off, Avantor has seen its pressure of challenges with the COVID headwinds, the inventory destock, softer demand in pharma, semis, et cetera. But just at this stage, could you talk about how '23 has played out so far versus your initial expectations at the start of the year? And what are you sort of